CEO of International Medical Consultants, IMC Radiology, and CMO of Levolta Pharma

Ketan Desai, MD, PhD, is the Founder and Chief Executive Officer of IMC Radiology, the founder and Chief Medical Officer of LeVolta Pharma (biotechnology), Founder and Chairperson of Omega Skin Solutions ... more

ALL CONTRIBUTIONS

E HH Review Of Present Therapies For Covid-19
A summary of authorized drugs for Covid-19, those in development, and those that have failed.
Read
E Pitfalls Of Biotechnology Investing
How capital distorts the availability of biotechnology companies.
Read
E Whither Flexion?
A new study highlights that there are likely fewer candidates for Flexion's star osteoarthritis treatment and this could affect the stock price of Flexion considerably.
Read
Is India's Economic Potential Over-Hyped?
An examination of the culture and demographics of India in relation to its economic potential.
Read
E Ford Model T And Personalized Medicine
While technology marches on, the economics of personalized medicines just don’t add up. Will they be like costly trinkets being displayed in a museum that we can watch at a distance but not own?
Read
E Only Trump Can Go To Russia
Investment implications of Trump's Russia and China policies.
Read

Comments

Latest Comments
Review Of Present Therapies For Covid-19
1 month ago

Thanks. Your point of placebo is well taken. Often though, it is not true placebo. The design is standard of care plus study drug versus standard of care plus placebo. The patients thus get the minimum of standard of care.

In this article: LLY, MRK, CYDY, REGN, HGEN, RLFTF
Review Of Present Therapies For Covid-19
1 month ago

Thanks

In this article: LLY, MRK, CYDY, REGN, HGEN, RLFTF
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
8 months ago

Written by Cytodyn insiders!! What conflict of interest!! Zero credibilty!! LOL!!!!

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
8 months ago

What an ignorant and biased rant. Look at these reviews on the status of immune response to COVID19. These are by independent scientists who, unlike you or Cytodyn, have no conflict of interest. They are peer reviewed and are in world class journals Sciene, Lancet. CCR5 is not a pathway that anyone of repute espouses.

www.sciencedirect.com/.../S1074761320301837

science.sciencemag.org/content/369/6508/eabc8511

www.thelancet.com/.../fulltext#seccestitle60

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
8 months ago

What a poor response. You DID NOT SHOW A SINGLE PEER REVIEWED INDEPENDENT ARTICLE ON CCR5 AND COVID19. We are not talking about HIV but COVID19. Stay on topic, will you, and stop dissembling the truth?

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
8 months ago

Scientific knowledge that Cytodyn pumpers dont know or deliberately obfuscate - neutrophils in COVID19 are determined by CCR8, and not CCR5. See article below. Leronlimab binds CCR5, not CCR8. Which is why other than Cytodyn, NOBODY IN THE SCIENTIFIC OR PHARMA COMMUNITY trusts cytodyn data.

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
8 months ago

Then don't respond. You must have a guilty conscience.

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
8 months ago

Which is why you should do your own due diligence and not listen to pumpers.

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
8 months ago

Not everyone against CYDY is a short. Some like me dislike lies and respond to restore clarity and science.

1. The drug works. In HIV, yes. In COVID19, no. It MISSED THE PRIMARY ENDPOINT

2. NASDAQ uplisting in process. Unlikely. IS NOT MEETING CRITERIA.

3. MHRA is positive on funding trials for EAMS patients in the U.K. MORE GOEBBLES DOUBLESPEAK.

4. NASH trial to start soon. That is a problem as the company is running out of money, and has no expertise in NASH. Most importantly, SCIENCE DOES NOT SUPPORT NASH.

5. Long Hauler Study to start soon. SEE 1 ABOVE. WON'T WORK.

6 At least 4 journal articles submitted for publication. YET NOTHING PUBLISHED.

7. Leronlimab crosses the blood-brain barrier. SO WHAT? NO SCIENCE TO SUPPORT ANY CNS INDICATION.

8. GILD bought a comparable drug platform with an inferior safety profile for $21 billion. BUT IMMUNOMEDICS DRUG WORKS, LMAB IS NOT AS GOOD. IF LMAB IS SO GOOD, WHY HAS NO PHARMA COMPANY APPROACHED IT? NO VC?

9. MANAGEMENT HAS NO DRUG DEVELOPMENT EXPERIENCE. ONLY EXPERIENCE IN BEATING WIVES AND SELLING FAKE INDIAN ARTIFACTS.

In this article: CYDY
1 to 10 of 21 comments
1 2 3

STOCKS I FOLLOW

ABT Abbott Laboratories
AMGN Amgen Inc.
BMY Bristol-Myers Squibb Company
MRK Merck & Co Inc.
VVUS Vivus, Inc.

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications

Germs of War
Ketan Desai
BookSurge Publishing
08/21/2002
A book where bioterrorism meets international intrigue, politics, and religious fundamentalism.